Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9
dc.creator | Kerenidi T., Kazakou A.P., Lada M., Tsilioni I., Daniil Z., Gourgoulianis K.I. | en |
dc.date.accessioned | 2023-01-31T08:43:15Z | |
dc.date.available | 2023-01-31T08:43:15Z | |
dc.date.issued | 2016 | |
dc.identifier | 10.1080/07357907.2016.1223301 | |
dc.identifier.issn | 07357907 | |
dc.identifier.uri | http://hdl.handle.net/11615/74866 | |
dc.description.abstract | Osteopontin (OPN) is a multifunctional cytokine involved in carcinogenesis. Serum levels of OPN, vascular endothelial growth factor (VEGF), and matrix metalloproteinase-9 (MMP-9) were measured by ELISA in 90 lung cancer patients. OPN levels were elevated in patients compared to controls (p <.0001). Smokers, patients with worse performance status, and weight loss exhibited higher OPN levels (p =.0012,.00036, and.0003, respectively). Increased OPN levels were associated with worse survival (p =.0018). Finally, OPN levels were positively correlated with both VEGF (p =.0008) and MMP-9 (p <.0001). OPN might serve as a prognostic biomarker, and the positive correlation between OPN and both VEGF and MMP-9 could implicate new insights in tumor angiogenesis. © 2016 Taylor & Francis Group, LLC. | en |
dc.language.iso | en | en |
dc.source | Cancer Investigation | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84987654721&doi=10.1080%2f07357907.2016.1223301&partnerID=40&md5=4517ae97b02ba0e69dce4db662c69fb2 | |
dc.subject | gelatinase B | en |
dc.subject | osteopontin | en |
dc.subject | vasculotropin | en |
dc.subject | gelatinase B | en |
dc.subject | osteopontin | en |
dc.subject | tumor marker | en |
dc.subject | vasculotropin A | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | cancer patient | en |
dc.subject | cancer prognosis | en |
dc.subject | cancer survival | en |
dc.subject | cohort analysis | en |
dc.subject | comparative study | en |
dc.subject | controlled study | en |
dc.subject | enzyme linked immunosorbent assay | en |
dc.subject | female | en |
dc.subject | human | en |
dc.subject | lung cancer | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | middle aged | en |
dc.subject | non small cell lung cancer | en |
dc.subject | overall survival | en |
dc.subject | priority journal | en |
dc.subject | prospective study | en |
dc.subject | protein blood level | en |
dc.subject | small cell lung cancer | en |
dc.subject | smoking | en |
dc.subject | weight reduction | en |
dc.subject | biopsy | en |
dc.subject | blood | en |
dc.subject | cancer grading | en |
dc.subject | cancer staging | en |
dc.subject | case control study | en |
dc.subject | Lung Neoplasms | en |
dc.subject | mortality | en |
dc.subject | neovascularization (pathology) | en |
dc.subject | prognosis | en |
dc.subject | Aged | en |
dc.subject | Biomarkers, Tumor | en |
dc.subject | Biopsy | en |
dc.subject | Case-Control Studies | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Lung Neoplasms | en |
dc.subject | Male | en |
dc.subject | Matrix Metalloproteinase 9 | en |
dc.subject | Middle Aged | en |
dc.subject | Neoplasm Grading | en |
dc.subject | Neoplasm Staging | en |
dc.subject | Neovascularization, Pathologic | en |
dc.subject | Osteopontin | en |
dc.subject | Prognosis | en |
dc.subject | Vascular Endothelial Growth Factor A | en |
dc.subject | Taylor and Francis Ltd | en |
dc.title | Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9 | en |
dc.type | journalArticle | en |
Fichier(s) constituant ce document
Fichiers | Taille | Format | Vue |
---|---|---|---|
Il n'y a pas de fichiers associés à ce document. |